{"symbol":"BMY","fiscalQuarter":"Q1-2017","reportDate":"2017-04-27","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q1-2017","postBrief":{"headline":"Bristol Myers Squibb Beats on EPS, Stock Up 3.53%","keyNumbers":[{"metric":"EPS","actual":"$0.84","expected":"N/A","surprise":"+13.33%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are pleased with our EPS performance this quarter.","Our focus remains on delivering innovative therapies."],"summary":"Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific guidance for future quarters."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Bristol Myers Squibb's strong EPS performance indicates effective cost management and operational efficiency. The stock's positive reaction of 3.53% suggests investor confidence in the company's current trajectory, despite the lack of revenue data and future guidance. Investors may view the EPS beat as a sign of resilience in a competitive market.","metaDescription":"Bristol Myers Squibb (BMY) Q1 2017 earnings: EPS beat by 13.33%. Stock up 3.53%. Full breakdown."}}